Combined depolymerization therapy for enhancing colorectal cancer radiotherapy sensitivity
In the treatment of colorectal cancer, zinc-aluminum layered dihydroxide material loaded with ethylenediaminetetraacetic acid destroys tumor cell connections and improves the hypoxic environment, enhances the effect of radiotherapy, solves the problem of inefficient chemotherapy and radiotherapy in low-level colorectal cancer, and provides a simple, non-invasive and efficient treatment strategy.
Patent Information
- Application Number
- CN202510536182.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-27
- Publication Date
- 2025-07-25
AI Technical Summary
Chemotherapy and radiotherapy for low-level colorectal cancer are inefficient and have serious systemic toxic side effects. The hypoxic environment causes tumor cells to tolerate radiotherapy, affecting the treatment effect.
Zn-aluminum layered dihydroxide material (LDH/EDTA) loaded with ethylenediaminetetraacetic acid is used to enter the colorectum through rectal perfusion, selectively attach to the tumor area, release EDTA chelates calcium ions, disrupts cell connections, improves hypoxic environment, and enhances tumor sensitivity through combined radiotherapy treatment.
The loose and hypoxic environment of tumor cells has been improved, the sensitivity of tumors to radiotherapy has been enhanced, the treatment effect has been improved, and systemic toxicity has been reduced, providing a simple, non-invasive and efficient treatment strategy.
Smart Images

Figure CN120360981A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a combined depolymerization therapy for enhancing the radiosensitivity of colorectal cancer, belonging to the field of biomedical technology. Background Art
[0002] Colorectal cancer is a clinically common malignant tumor of the cavity. The latest statistical data show that the global incidence of colorectal cancer ranks third, the mortality ranks second, and the five-year survival rate is ≤ 10%. The treatment plan for colorectal cancer in clinical medicine is mainly surgical resection, supplemented by chemotherapy and radiotherapy. Patients with mid-low rectal cancer (tumor distance from the anal verge < 10 cm) account for 35% - 40% of all colorectal cancer patients. Surgical resection of the tumor cannot preserve the anal function, and conventional treatments such as chemotherapy and radiotherapy are inefficient and have serious systemic toxic side effects.
[0003] During radiotherapy, oxygen molecules participate in the process of ionizing radiation to damage DNA. There are two explanations for its principle: (1) Ionizing radiation such as X-rays can activate oxygen molecules to generate various forms of reactive oxygen species, and reactive oxygen free radicals can effectively damage various important biomolecules in cells including DNA. (2) Ionizing radiation can directly damage DNA, but under hypoxic conditions, this DNA damage can be repaired by intracellular DNA repair enzymes, resulting in cell tolerance to radiotherapy; while in an environment where oxygen molecules are present, since oxygen molecules can quickly react with DNA damage sites to prevent cell repair of it, the cells are more easily killed by rays. Regardless of which of the above reasons, it can be explained that cells with high oxygen concentration are more easily killed by rays, while tumor cells in a hypoxic state have the ability to resist ionizing radiation several times more than normal oxygen-containing cells. Therefore, improving the hypoxic environment of tumors can greatly improve the treatment efficiency of radiotherapy. Summary of the Invention
[0004] In order to solve the problem of low efficacy of low rectal cancer, the present invention proposes a combined therapy using a zinc-aluminum layered double hydroxide (LDH) material loaded with ethylenediaminetetraacetic acid (EDTA) for depolymerization treatment to enhance the radiotherapy efficacy. By this method, the intercellular connections can be efficiently disrupted, thereby making the tumor loose and improving the tumor hypoxic environment, ultimately enhancing the radiosensitivity of the tumor and further enhancing the efficacy.
[0005] In a first aspect, the present invention provides the use of an LDH / EDTA layered double hydroxide material in the preparation of an anti-colorectal cancer drug for use in combination with radiotherapy.
[0006] Preferably, the drug is an anti-colorectal cancer drug that enhances the radiosensitivity of colorectal cancer.
[0007] Preferably, the colorectal cancer is mid-low colorectal cancer.
[0008] Preferably, the LDH / EDTA layered double hydroxide material comprises zinc-aluminum layered double hydroxide (LDH) as a carrier and ethylenediaminetetraacetic acid (EDTA) loaded between the layers of the zinc-aluminum layered double hydroxide; wherein, the mass ratio of the ethylenediaminetetraacetic acid to the zinc-aluminum layered double hydroxide is more than 10%.
[0009] Preferably, the molar ratio of Zn to Al in the zinc-aluminum layered double hydroxide is 1.5:1 to 3:1.
[0010] Preferably, the ethylenediaminetetraacetic acid is intercalated between the layers of the zinc-aluminum layered double hydroxide by anion exchange.
[0011] Preferably, the particle size of the LDH / EDTA layered double hydroxide material is 700 - 1500 nm.
[0012] Preferably, in the acidic microenvironment of the tumor, the LDH / EDTA layered double hydroxide material releases EDTA to chelate calcium ions, inhibits the expression of corresponding calcium ion-dependent proteins, destroys the connections of tumor cells, causes the tumor cells to shed, and is wrapped by the LDH / EDTA layered double hydroxide material to inhibit tumor metastasis.
[0013] Preferably, the LDH / EDTA layered double hydroxide material improves the hypoxic environment at the tumor site to enhance the sensitivity of the tumor to radiotherapy.
[0014] Preferably, the operation process of the anti-colorectal cancer drug used in combination with radiotherapy includes: Step (1) introducing the LDH / EDTA layered double hydroxide material into the colorectum by means of rectal perfusion; Step (2) after the LDH / EDTA layered double hydroxide material selectively adheres to the tumor region, it releases EDTA, thereby destroying cell connections and improving the tumor hypoxic environment; Step (3) the LDH / EDTA layered double hydroxide material tightly wraps the free tumor cells exfoliated layer by layer, making them unable to metastasize through the muscular layer or distally through the nearby lymph nodes, and is excreted out of the body with excretion; Step (4) after perfusing the LDH / EDTA layered double hydroxide material, radiotherapy treatment is performed on the tumor to achieve efficient killing of the tumor and inhibit tumor growth.
[0015] Beneficial effects:
[0016] The present invention provides a new, simple, feasible, non-invasive and highly efficient strategy for treating colorectal cancer. Specifically, by disrupting tumor cell junctions, tumor cells are detached from the cancerous tissue, the cancerous tissue is loosened, the hypoxic environment of the cancerous tissue is improved, and in combination with subsequent radiotherapy courses, efficient killing of the tumor is achieved. In the present invention, the LDH / EDTA layered double hydroxide material can selectively adhere to the tumor area and adhere to the tumor tissue. Subsequently, the released EDTA chelates calcium ions between cells, inhibits the expression of calcium ion-dependent proteins, thereby disrupting cell junctions, can directly improve the hypoxic environment at the tumor site from the tissue level, has little impact on normal tissues, and has low systemic toxicity. Description of the Drawings
[0017] Figure 1 Transmission electron microscopy (TEM) photograph of the material system LDH / EDTA prepared in Example 1; Figure 2 XRD patterns of the material systems LDH and LDH / EDTA prepared in Example 1; Figure 3 FT-IR spectra of the material systems EDTA, LDH, and LDH / EDTA prepared in Example 1; Figure 4 Transmission electron microscopy element mapping diagram of the material system LDH / EDTA prepared in Example 1; Figure 5 EDS energy spectrum and ICP-OES element quantitative analysis of the material system LDH / EDTA prepared in Example 1; Figure 6 Zeta potential analysis of the material systems LDH and LDH / EDTA prepared in Example 1; Figure 7 Detection of the release behavior of EDTA in the material system LDH / EDTA prepared in Example 1 in acidic PBS (pH 6.5) and PBS (pH 7.4); Figure 8 Confocal photographs for evaluating the targeting adhesion of the material system LDH / EDTA prepared in Example 1 to colon cancer cells (CT26) and immortalized intestinal epithelial cells (MCEC); Figure 9 Tumor adhesion results of the material system LDH / EDTA prepared in Example 1; Figure 10 Changes in tumor size observed by colonoscopy in mice of different groups during the treatment process; Figure 11 Anatomical diagrams of the intestines of mice in different groups after the treatment; Figure 12 The largest tumor among multiple tumors in the intestines of mice in different groups; Figure 13 Immunofluorescence sections of tumors in mice of different groups; Figure 14 Tissue section images of various organs such as the heart, liver, spleen, lungs, and kidneys of healthy C57BL / 6 mice after depolymerization plus radiotherapy treatment. Specific implementation manners
[0018] The present invention is further illustrated by the following implementation manners. It should be understood that the following implementation manners are only used to illustrate the present invention and do not limit the present invention.
[0019] The effect of radiotherapy on tumor killing requires the participation of oxygen. Relieving the tumor hypoxic environment at the tissue level is more efficient and safe than other drug methods. Cell junctions mainly include tight junctions, adherens junctions, and desmosome and hemidesmosome structures. Some key proteins expressed in these junctions are calcium-dependent, such as E-cadherin in typical adherens junctions, desmoglein and desmocollin in desmosome structures, and their conformations can only be stable in the presence of calcium. As a classical metal ion chelator, EDTA can chelate calcium ions and disrupt the expression of calcium-dependent proteins, and is used to gently disrupt cell-cell junctions by non-enzymatic methods to isolate cells from tissues. Developing a convenient, fast, non-invasive, and highly efficient new treatment strategy for colorectal cancer and constructing a new combined therapy of depolymerization therapy and radiotherapy are crucial.
[0020] The present invention provides the application of LDH / EDTA layered double hydroxide materials in the preparation of anti-colorectal cancer drugs for combined use with radiotherapy. That is, the application of the depolymerization therapy of LDH / EDTA layered double hydroxide materials combined with radiotherapy in the treatment of colorectal cancer. By this method, cell-cell junctions can be efficiently disrupted, thereby making the tumor loose and improving the tumor hypoxic environment, and ultimately enhancing the sensitivity of the tumor to radiotherapy.
[0021] The LDH / EDTA layered double hydroxide material is a zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid. Selecting a zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid to disrupt tumor cell junctions, and this process is called the depolymerization of tumors. The depolymerization therapy can disrupt tumor cell junctions and improve the hypoxic environment at the tumor site, which is of great significance for improving the radiotherapy treatment effect in subsequent combined radiotherapy. Through the depolymerization treatment of tumors, the hypoxic environment at the tumor site can be relieved, combined with radiotherapy, and thus efficient treatment of colorectal cancer can be achieved.
[0022] LDH has good biocompatibility, low toxicity and other characteristics, providing safety guarantees in the application of the biomedical field. LDH has a high drug-loading capacity between layers and a pH-responsive drug release performance. At the same time, the layered double hydroxide (LDH) surface carries a positive charge, and it has good selective adhesion to the negative charge generated by excessive glycolysis on the tumor surface. Therefore, the use of LDH can release drugs at the tumor site well while ensuring biological safety. In this study, the inventor determined to select LDH as the material carrier.
[0023] Taking the mass of the zinc-aluminum layered double hydroxide as 100 wt%, the content of the ethylenediaminetetraacetic acid is greater than 10 wt%. Preferably, the mass ratio of the ethylenediaminetetraacetic acid to the zinc-aluminum layered double hydroxide is 20 wt% - 35 wt%.
[0024] The molar ratio of Zn and Al in the zinc-aluminum layered double hydroxide can be 1.5:1 - 3:1.
[0025] The particle size of the LDH / EDTA layered double hydroxide material can be 700 - 1500 nm.
[0026] In the zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid, the ethylenediaminetetraacetic acid is intercalated into the interlayer of the zinc-aluminum layered double hydroxide through anion exchange. That is to say, LDH / EDTA is a zinc-aluminum layered double hydroxide (LDH) with ethylenediaminetetraacetic acid (EDTA) intercalated in the interlayer.
[0027] In the present invention, in the acidic microenvironment of the tumor, the LDH / EDTA layered double hydroxide material releases EDTA to chelate calcium ions, inhibits the expression of corresponding calcium ion-dependent proteins, thereby destroying tumor cell connections, causing tumor cells to fall off and be wrapped by the LDH / EDTA layered double hydroxide material to inhibit tumor metastasis. While treating tumors, it improves the hypoxic environment at the tumor site to enhance the sensitivity of tumors to radiotherapy.
[0028] There is still a significant technical gap between the functional role of the material itself and the clinical treatment strategy. The present invention first proposes that the LDH / EDTA layered double hydroxide material can relieve the hypoxic environment in the tumor area and can be used in combination with radiotherapy to treat colorectal cancer. There is a coupling relationship between tumor depolymerization and combined radiotherapy. The technical solution proposed by the present invention is to depolymerize tumor tissues through the LDH / EDTA material, thereby significantly improving the hypoxic microenvironment and further enhancing the radiotherapy sensitivity to form a synergistic therapeutic effect. This treatment logic is based on a systematic understanding of the tumor microenvironment, cell connection mechanism and radiotherapy mechanism, involving multidisciplinary cross-knowledge and innovative strategy design.
[0029] The previous exploration only involved the LDH / EDTA layered double hydroxide material itself, which disrupted the connections of tumor cells and achieved the purpose of treating tumors through a non-lethal method. However, the present invention aims to treat tumors by killing tumor cells through radiotherapy. Combining radiotherapy and relieving the hypoxic environment at the tumor site to enhance the effect of radiotherapy is a new exploration and application of the present invention. Therefore, based on the novel idea of combining this material with radiotherapy for the treatment of colorectal cancer, the present invention constructs a treatment system with a synergistic sensitization effect.
[0030] It should be understood that the LDH / EDTA layered double hydroxide material obtained by any preparation method is applicable to the present invention. For example, the LDH / EDTA layered double hydroxide material can be prepared by the homogeneous alkali solution method or the urea decarburization method. The following will exemplarily illustrate the preparation method of the LDH / EDTA layered double hydroxide material.
[0031] In an alternative embodiment, it is prepared by the urea decarburization method. For example, a mixed solution containing a zinc source, an aluminum source, and urea is placed in an oil bath at 80-140°C, and refluxed in an argon-protected atmosphere for 1-20 hours. After the reaction ends, the solution is allowed to cool, and a pale white suspension is collected. After natural sedimentation, it is washed three times with deionized water, and decarburization treatment is carried out in an acidic environment for 4-12 hours. The decarburization operation is repeated twice under the same conditions, each time for 2-6 hours. After decarburization, it is allowed to settle naturally, washed with deionized water to remove the residual solution. After removing the supernatant, it is mixed with an EDTA aqueous solution and reacted at 80°C-120°C for 2-6 hours. A large amount of EDTA is inserted into the LDH interlayer through anion exchange and can be released in a slightly acidic body environment (pH 6.5). After the LDH / EDTA is prepared, it is filtered and washed three times with water, and the powder is stored in a 4°C refrigerator after being freeze-dried. Subsequently, it is prepared as needed, for example, dispersed in cell culture medium or physiological saline according to the concentration. Among them, the addition concentration of LDH / EDTA in the cell culture medium or physiological saline can be 60 mg / Kg. This material, LDH / EDTA, has no obvious acute or chronic pathological toxicity and abnormalities to the main tissues and blood indexes of the body, and has good in vivo systemic safety.
[0032] In an alternative embodiment, the mass ratio of disodium ethylenediaminetetraacetate to the zinc source is 0.5:1-3:1. The zinc source can be selected from zinc nitrate and / or zinc chloride, etc. The aluminum source can be selected from aluminum nitrate and / or aluminum chloride, etc. Among them, the mass ratio of the zinc source to the aluminum source can be 1.5:1-3:1. The mass ratio of urea to the zinc source can be 4:1-8:1. The mass concentration of the EDTA aqueous solution can be 0.01%-1%. The acidic environment can be obtained by adjusting the reaction solution with dilute hydrochloric acid. For example, the dilute hydrochloric acid solution is obtained by mixing 50 mL of 1M NaCl solution and 50 μL of hydrochloric acid evenly.
[0033] In the above-mentioned LDH / EDTA synthesis reaction, it is necessary to carry out the reaction under an argon protection atmosphere to avoid the entry of carbon dioxide in the air into the system, so as to prevent the formation of carbonate ions from inserting into the LDH interlayer and being difficult to displace.
[0034] Taking the treatment of colorectal cancer by depolymerization combined with radiotherapy as an example, its operation process may include: introducing the LDH / EDTA layered double hydroxide material into the colorectal cancer by means of rectal perfusion; after the LDH / EDTA layered double hydroxide material selectively adheres to the tumor area, it releases EDTA, thereby destroying cell junctions and improving the hypoxic environment of the tumor; the LDH / EDTA layered double hydroxide material tightly wraps the free tumor cells exfoliated layer by layer, making it impossible for them to metastasize to the muscular layer or distally through the nearby lymph nodes, and being excreted out of the body with excrement; within a period of time after the material perfusion, radiotherapy is carried out on the tumor to achieve efficient killing of the tumor and inhibit tumor growth. The timing of radiotherapy can be set as needed.
[0035] The following further lists examples to illustrate the present invention in detail. It should also be understood that the following examples are only used to further illustrate the present invention and cannot be construed as limiting the protection scope of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the above content of the present invention all fall within the protection scope of the present invention. The specific process parameters and the like in the following examples are also only an example within a suitable range, that is, those skilled in the art can make selections within a suitable range through the description herein, rather than being limited to the specific values in the following examples.
[0036] Example 1
[0037] Synthesis of LDH / EDTA: Weigh Zn(NO3)2·6H2O (0.594 g), Al(NO3)3·9H2O (0.375 g) and urea (3 g), and place them in a beaker for ultrasonic dissolution respectively. Add deionized water to make the volume up to 100 mL, pour it into a three-necked flask, and add deionized water. Start mechanical stirring at 800 r / min at room temperature. Insert the ventilation valve below the liquid level, and introduce high-purity argon gas for 5 min to expel air. Set the temperature of the oil bath to 100 °C, install a condenser, and reflux under the condition of high-purity argon gas as the protective gas. After the self-heating ends, turn off the argon gas and continue to react at 100 °C for 18 h. After the reaction is completed, wait for the solution to cool, collect the light white suspension, let it settle naturally, then wash it three times with deionized water, and perform decarbonization treatment with a dilute hydrochloric acid solution (50 mL of 1 M NaCl solution + 50 μL of hydrochloric acid mixed evenly) for 8 h. Repeat the decarbonization operation twice under the same conditions, each time for 4 h. After decarbonization, let it settle naturally, wash it three times with deionized water to remove the residual solution. After removing the supernatant, mix it with an EDTA solution (0.5 g of EDTA dissolved in 100 ml of deionized water), place it in a three-necked flask, and react at 100 °C for 4 h. Centrifuge at 10000 r / min for 10 min. Pour out the supernatant, and redisperse the precipitate in deionized water. Pour the redispersed suspension into a vacuum filtration device, filter it through a filter membrane (1.2 μm), add deionized water, and repeatedly blow the filtrate with a disposable dropper. After filtration, place the filter cake in a vacuum freeze dryer. After 4 h, grind the sample and perform ultraviolet ozone disinfection to obtain the LDH / EDTA sample, which is encapsulated in a sample tube and can be stored at room temperature for one week and stored in the dark at 4 °C for a long time.
[0038] Synthesis of LDH. The difference between preparing LDH and LDH / EDTA is only that disodium ethylenediaminetetraacetate is not added during the preparation of LDH.
[0039] Figure 1 It is the transmission electron microscope (TEM) photograph of the material system LDH / EDTA prepared in Example 1. As can be seen from the figure, the morphology of the prepared material is two-dimensional sheet-like, with uniform dispersion and a size of about 1 μm.
[0040] Figure 2 It is the XRD pattern of the material systems LDH and LDH / EDTA prepared in Example 1. As can be seen from the figure, the basic diffraction peaks of the planes (003), (006) and (012) of LDH are the characteristic peaks of the layered structure, but there are certain differences in the peak positions with or without EDTA intercalation. Compared with LDH, the characteristic peaks of EDTA / LDH shift towards smaller angles because EDTA has a longer van der Waals pair end length, resulting in an interlayer spacing d 003Increased, confirming that EDTA was successfully inserted into the interlayer of LDH through an anion exchange reaction.
[0041] Figure 3 FT-IR spectra of the material systems LDH, LDH / EDTA, and EDTA prepared in Example 1. As can be seen from the figure, the broad absorption band at ~1646 cm -1 is the stretching vibration of hydrogen bonds and the bending vibration of water in LDH. The sharp absorption band at 1385 cm -1 is caused by the stretching vibration mode of nitrate ions in the interlayer of LDH. In the LDH / EDTA spectrum, the strong absorption bands at 1601 cm -1 and 1400 cm -1 are caused by the symmetric and antisymmetric vibrations of the COO group in EDTA, proving that EDTA was inserted into LDH.
[0042] Figure 4 and Figure 5 are the transmission electron microscope element mapping diagram, the corresponding EDS energy spectrum, and the ICP-OES element quantitative analysis of the material system LDH / EDTA prepared in Example 1, respectively. As can be seen from the figure, in the framework of the prepared LDH / EDTA material system, through the point mapping and line scanning of the corresponding Zn, Al, and O elements by transmission electron microscopy, a uniform distribution of Zn, Al, and O can be seen on the surface of LDH / EDTA, indicating the successful preparation of zinc-aluminum LDH. Through ICP-OES element quantitative analysis, the zinc-aluminum molar ratio in this LDH / EDTA material is 2:1.
[0043] Figure 6 Zeta potential analysis of the material system LDH / EDTA prepared in Example 1. As can be seen from the figure, both the surfaces of LDH and LDH / EDTA are positively charged.
[0044] Figure 7 Detection of the release behavior of EDTA from LDH / EDTA prepared in Example 1 in acidic PBS (pH 6.5) and PBS (pH 7.4). It can be known that the release of EDTA is relatively fast within two hours, and then it continues to release slowly. Moreover, the release rate in acidic PBS is much higher than that in neutral PBS, and the release amount can reach 25 wt% within 24 h.
[0045] Example 2
[0046] Cell application effect experiment
[0047] 2.1 Evaluation of cell adhesion of materials
[0048] Experimental materials and instruments: LDH and LDH / EDTA prepared in Example 1, fluorescein isothiocyanate FITC dye, nuclear Hoechst dye, cell membrane Dil dye.
[0049] Experimental method: Stir and stain FITC with materials LDH and LDH / EDTA. Colon cancer cells CT26 and immortalized intestinal epithelial cells MCEC were seeded on confocal dishes. After cell membrane and nucleus staining, they were co-incubated with LDH and LDH / EDTA conjugated with FITC at a concentration of 200 ppm for 30 min respectively, and observed under a 60× oil immersion objective of a confocal microscope (FluoView FV1000) at 15 min and 30 min.
[0050] Experimental results: Figure 8 Confocal microscopy images for the evaluation of the targeting adhesion of LDH / EDTA prepared in Example 1 to colon cancer cells CT26 and immortalized intestinal epithelial cells MCEC. As shown in the figure, the green fluorescence is the material system of FITC, the red fluorescence is the cell membrane stained with Dil, and the blue fluorescence is the nucleus stained with Hoechst. At the same concentration, LDH / EDTA can adhere well to the surface of CT26 cells but not to the surface of MCEC cells within the same time period.
[0051] This selective adhesion has the following advantages: 1. Enhanced therapeutic targeting and reduced non-specific toxic side effects. Selective adhesion is the first step towards tumor-specific therapy. Compared with traditional drugs or treatment methods that are likely to damage healthy intestinal cells, the selectively adhesive materials can accumulate at the tumor site to form an enrichment effect, enhancing the local drug efficacy; avoiding interference with normal intestinal epithelial cells, reducing side effects such as intestinal barrier damage, bleeding, and diarrhea; improving patient tolerance and quality of life, facilitating the implementation of long-term treatment regimens. 2. Enhanced local retention and overcoming intestinal peristalsis and mucus barrier. The intestinal environment is complex, with factors such as continuous peristalsis, mucus secretion, and the participation of flora, making it easy for materials to be diluted and washed away. Selectively adhesive materials have the ability to "adhere" to cancer tissues, counteracting the repulsive clearance of the intestine; forming a "local drug reservoir" in the lesion area to enable the long-term action of the materials; effectively penetrating or attaching to the tumor mucus layer and epithelial interface, enhancing the depth of action.
[0052] 2.2 Evaluation of the tumor adhesion of materials
[0053] Experimental materials and instruments: LDH / EDTA prepared in Example 1, PBS, isoflurane.
[0054] Experimental method: Orthotopic colorectal cancer mice were deprived of food and water for 12 hours in advance. Anesthesia was induced using a 5 vol% isoflurane gas anesthesia machine, and the mice were fixed in a supine position, and anesthesia was maintained at a concentration of 1.5 vol%. The anus was wiped with 1 wt% chlorhexidine three times for disinfection, and then a catheter coated with lubricant was slowly inserted into the intestine, and 60 mg / kg of LDH / EDTA was infused according to the weight of the mice. Colonoscopy was performed on the same position of the intestine and the same tumor before and after infusion.
[0055] Experimental results: Figure 9 This is the tumor adhesion result of the material system LDH / EDTA prepared in Example 1. As shown in the figure, after the drug is infused, LDH / EDTA will selectively adhere to the tumor surface, but not to the intestinal surface, proving that the material has good selectivity for tumors.
[0056] Example 3
[0057] In vivo evaluation experiment
[0058] 3.1 Evaluation of the therapeutic effect on orthotopic low-middle-range colorectal cancer C57BL / 6 mice
[0059] Experimental materials: LDH and LDH / EDTA synthesized in Example 1, PBS, isoflurane, azomethane (AOM), dextran sulfate sodium (DSS).
[0060] Experimental methods:
[0061] AOM / DSS-induced in situ colorectal cancer mouse modeling: AOM was dissolved in PBS at 1 mg / ml, and female C57BL / 6 mice weighing about 20 g were used. Each mouse was intraperitoneally injected with AOM solution at 10 mg AOM per kilogram of body weight, and recorded as day-5. Five days later (day0), a 2wt% DSS solution was prepared: 4g of DSS powder was accurately weighed with an electronic balance, dissolved in water to 200ml, filtered and sterilized with a 0.22um filter, and the DSS solution was placed in a mouse drinking bottle. The mice were allowed to drink the DSS solution for 5 consecutive days (day0-day5), and then replaced with normal drinking water. Day6-day21, the mice were allowed to drink normal drinking water, and then replaced with 2wt% DSS solution. Day21-day26, the mice were allowed to drink 2wt% DSS solution for 5 consecutive days, and then replaced with normal drinking water. Day26-day42, the mice were allowed to drink normal drinking water, and then replaced with 2wt% DSS solution. From Day 42 to Day 47, the mice were allowed to drink 2 wt % DSS solution for 5 consecutive days, and then the solution was replaced with normal drinking water. From Day 47 to Day 100, the mice were allowed to drink normal drinking water.
[0062] Evaluation of the enhanced radiotherapy effect by depolymerization therapy: After the modeling period, colonoscopy was used to detect whether tumors had formed in the mice. The successful models were randomly divided into five groups (Control, PBS+RT, LDH+RT, LDH / EDTA, LDH / EDTA+RT). Before each treatment, the mice were deprived of food and water for 12 h, induced anesthesia with a 5 vol% isoflurane gas anesthetic machine, fixed in the supine position, and maintained anesthesia with a 1.5 vol% concentration. The anal area was wiped three times with 1% benzalkonium bromide for disinfection, and then a lubricated urinary catheter was slowly inserted into the intestine.
[0063] In the Control group, 1 ml of PBS solution was perfused into the intestine on days 1, 6, and 11 respectively; in the PBS+RT group, 1 ml of PBS solution was perfused into the intestine on days 1, 6, and 11 respectively, and radiotherapy with a dose of 6 Gy was performed on days 2, 7, and 12; in the LDH+RT group, 1 ml of LDH solution with a concentration of 60 mg / kg was perfused into the intestine according to the body weight of the mice on days 1, 6, and 11 respectively, and radiotherapy with a dose of 6 Gy was performed on days 2, 7, and 12; in the LDH / EDTA group, 1 ml of LDH / EDTA solution with a concentration of 60 mg / kg was perfused into the intestine on days 1, 6, and 11 respectively; in the LDH / EDTA+RT group, 1 ml of LDH / EDTA solution with a concentration of 60 mg / kg was perfused into the intestine on days 1, 6, and 11 respectively, and radiotherapy with a dose of 6 Gy was performed on days 2, 7, and 12.
[0064] After perfusion, the urinary catheter and the anus of the mice were clamped for 2 h, and then the urinary catheter was slowly withdrawn. Colonoscopy of the mice was observed on days 0, 12, and 30. The mice were sacrificed on day 30. After sacrificing the mice on day 30, the colorectal part of the mice was taken out, cut open to observe the final tumor size and photographed. At the same time, the heart, liver, spleen, lungs, kidneys and other organs of each group were taken out and observed.
[0065] Experimental results:
[0066] Figure 10 shows the changes in tumor size observed by colonoscopy in mice of different groups during the treatment process. The parts circled by the dotted lines in the figure are tumors. It can be seen that as the treatment progresses, the LDH / EDTA+RT group has a more excellent curative effect compared with the LDH / EDTA group and the conventional radiotherapy group, and the tumors are significantly smaller.
[0067] Figure 11 shows the intestinal anatomical diagrams of mice in different groups after the treatment. The arrows in the figure are tumors. It can be seen that as the treatment progresses, the LDH / EDTA+RT group has a more excellent curative effect compared with the LDH / EDTA group and the conventional radiotherapy group, and the tumors are significantly smaller, thus proving that the combined treatment of depolymerization and radiotherapy can significantly improve the radiotherapy treatment effect.
[0068] Figure 12 The largest tumor among multiple tumors in the intestines of five mice in different groups. It can be seen that the LDH / EDTA+RT group combining depolymerization and radiotherapy has a more significant effect on reducing the number and size of tumors compared with the radiotherapy group alone.
[0069] 3.2 Verification of treatment mechanism
[0070] Experimental materials: Tumor sections of mice in different groups in the in vivo evaluation experiment
[0071] Experimental method: Immunofluorescence detection of hypoxia-inducible factor (HIF-1), γ-H2AX (DNA damage marker), E-cadherin (E-cad), etc. on different tumor sections. By comparing the contents of tumor markers in different groups, it is verified that the depolymerization therapy can enhance the efficacy of radiotherapy.
[0072] Experimental results: Figure 13 Immunofluorescence sections of tumors in different groups. As shown in the figure, the yellow fluorescence is HIF-1. The yellow fluorescence in the LDH / EDTA and LDH / EDTA+RT groups is darker than that in other groups, indicating a decrease in the content of HIF-1, which can prove that the hypoxic environment at the tumor sites in these two groups has been improved. The red fluorescence is γ-H2AX. It can be seen from the figure that the red fluorescence in the LDH / EDTA+RT treatment group combining depolymerization and radiotherapy is brighter than that in the PBS+RT and LDH+RT groups, indicating that the DNA damage in this group is more severe, thus proving that the depolymerization treatment can enhance the efficacy of radiotherapy. The purple fluorescence is E-cad. It can be seen from the figure that the fluorescence in the LDH / EDTA and LDH / EDTA+RT groups is darker than that in the other two groups, indicating that the depolymerization therapy can destroy the E-cadherin of tumors. Based on the above results, it can be concluded that the depolymerization therapy can improve the hypoxic environment of tumors and thus enhance the efficacy of radiotherapy.
[0073] 3.3 In vivo tissue toxicity test
[0074] Experimental materials: LDH / EDTA synthesized in Example 1, PBS.
[0075] Experimental method: Healthy female C57BL / 6 mice were randomly divided into three groups. The first group, as the Control group, was untreated healthy mice used as a control and were sacrificed on day 30. The second group received an intestinal perfusion of 1 ml of a LDH / EDTA solution with a concentration of 60 mg / kg on days 1, 6, and 11, and were treated with a radiation dose of 6 Gy on days 2, 7, and 12, and were sacrificed after the treatment. The third group received an intestinal perfusion of 1 ml of a LDH / EDTA solution with a concentration of 60 mg / kg on days 1, 6, and 11, and were treated with a radiation dose of 6 Gy on days 2, 7, and 12, and the mice were sacrificed on day 30. The main tissues (heart, liver, spleen, lung, kidney) of the sacrificed mice in each group were taken for hematoxylin and eosin (H&E) staining for histological analysis.
[0076] Experimental results: Figure 14 Tissue section diagrams of various organs such as the heart, liver, spleen, lung, and kidney of healthy C57BL / 6 mice after depolymerization plus radiotherapy treatment. It can be seen from the figure that after the combined treatment of depolymerization and radiotherapy, there were no obvious toxic reactions in the heart, liver, spleen, lung, and kidney, indicating that this combined therapy has good biosafety.
[0077] In summary, it can be seen that the combined therapy provided by the present invention has good selective adhesion. After intestinal perfusion, the material can be enriched in the tumor area to disrupt cell junctions, thereby improving the hypoxic environment at the tumor site, and then enhancing the sensitivity of the tumor to radiotherapy. In addition, this material also has low toxic and side effects, which has important value and significance for the development and application of medical treatment technologies for bladder cancer.
Claims
1. Use of a LDH / EDTA layered double hydroxide material in the preparation of an anti-colorectal cancer drug for combined use with radiotherapy.
2. The application according to claim 1, wherein The drug is an anti-colorectal cancer drug that enhances the radiosensitivity of colorectal cancer.
3. The application according to claim 1 or 2, characterized in that, The colorectal cancer is mid-low rectal cancer.
4. The application according to any one of claims 1 to 3, characterized in that The LDH / EDTA layered double hydroxide material includes zinc-aluminum layered double hydroxide as a carrier and ethylenediaminetetraacetic acid loaded between the layers of the zinc-aluminum layered double hydroxide; wherein, the mass ratio of the ethylenediaminetetraacetic acid to the zinc-aluminum layered double hydroxide is more than 10%.
5. The application according to claim 4, characterized in that The molar ratio of Zn to Al in the zinc-aluminum layered double hydroxide is 1.5:1 to 3:
1.
6. The application according to claim 4 or 5, characterized in that, The ethylenediaminetetraacetic acid is intercalated between the layers of the zinc-aluminum layered double hydroxide through anion exchange.
7. The application according to any one of claims 1 to 6, characterized in that, The particle size of the LDH / EDTA layered double hydroxide material is 700 - 1500 nm.
8. The application according to any one of claims 1 to 7, characterized in that, In the slightly acidic microenvironment of the tumor, the LDH / EDTA layered double hydroxide material releases EDTA to chelate calcium ions, inhibits the expression of corresponding calcium ion-dependent proteins, disrupts tumor cell junctions, causes tumor cells to shed, and is encapsulated by the LDH / EDTA layered double hydroxide material to inhibit tumor metastasis.
9. The application according to any one of claims 1 to 8, characterized in that, The LDH / EDTA layered double hydroxide material improves the hypoxic environment at the tumor site to enhance the radiosensitivity of the tumor.
10. The application according to any one of claims 1 to 9, characterized in that, The operation process of the anti-colorectal cancer drug for combined use with radiotherapy includes: Step (1) Introduce the LDH / EDTA layered double hydroxide material into the colorectum by the rectal perfusion method; Step (2) After the LDH / EDTA layered double hydroxide material selectively adheres to the tumor area, it releases EDTA, thereby disrupting cell junctions and improving the tumor hypoxic environment; Step (3) The LDH / EDTA layered double hydroxide material tightly wraps the free tumor cells obtained by layer-by-layer exfoliation, preventing them from metastasizing to the muscular layer or distally through the nearby lymph nodes, and being excreted out of the body with excretion; Step (4) After perfusing the LDH / EDTA layered double hydroxide material, perform radiotherapy on the tumor to achieve efficient killing of the tumor and inhibit tumor growth.
